钇-90 树脂微球经动脉放射栓塞与阿替利珠单抗-贝伐珠单抗治疗不可切除肝细胞癌的疗效:一项匹配调整间接比较
在无头对头试验的情况下,本研究采用匹配调整间接比较,对比钇-90 树脂微球经动脉放射栓塞(TARE)与阿替利珠单抗-贝伐珠单抗(AB)在晚期不可切除肝细胞癌中的疗效。结果示 TARE 组与 AB 组中位总生存分别为 15.0 个月与 14.9 个月(HR=0.980,95%CI 0.658-1.461,p=0.922),中位无进展生存分别为 4.4 个月与 6.8 个月(HR=0.745,95%CI 0.544-1.022,p=0.068),客观缓解率分别为 19.8% 与 25%(AB 的 OR=1.386,95%CI 0.746-2.668,p=0.306)。作者认为 TARE 可能获得与 AB 相当的疗效结局。
要点
- TARE 组与 AB 组中位总生存分别为 15.0 个月与 14.9 个月,HR=0.980(95%CI 0.658-1.461,p=0.922)。
- TARE 组与 AB 组中位无进展生存分别为 4.4 个月与 6.8 个月,HR=0.745(95%CI 0.544-1.022,p=0.068)。
- TARE 组与 AB 组客观缓解率分别为 19.8% 与 25%,AB 的 OR=1.386(95%CI 0.746-2.668,p=0.306)。
核心结论
- 在接受治疗的肝细胞癌患者中,使用钇-90 树脂微球的 TARE 与 AB 相比可能获得相当的疗效结局。
研究设计与样本
- 采用非锚定匹配调整间接比较,TARE 组使用 SARAH 随机对照试验的患者水平数据(基础分析为符合方案集),AB 组使用 AB-real 研究的聚合真实世界数据。
- 从文献中确定的预后变量与效应修饰因素包括:病因、大血管侵犯、美国东部肿瘤协作组体能状态评分、甲胎蛋白水平和白蛋白-胆红素评分。
- 对 SARAH 试验患者赋权以平衡两研究间的基线特征并反映 AB-real 患者的特征。
- 总生存和无进展生存分析纳入 140 例接受 TARE 的患者,缓解率分析纳入 131 例接受 TARE 的患者,与 202 例接受 AB 的患者进行比较。
- 敏感性分析使用 SARAH 的意向性治疗数据。
主要发现
- TARE 组与 AB 组的中位总生存分别为 15.0 个月与 14.9 个月(HR=0.980;95%CI 0.658-1.461;p=0.922)。
- TARE 组与 AB 组的中位无进展生存分别为 4.4 个月与 6.8 个月(HR=0.745;95%CI 0.544-1.022;p=0.068)。
- TARE 组与 AB 组的客观缓解率分别为 19.8% 与 25%(AB 的 OR=1.386,95%CI 0.746-2.668;p=0.306)。
- 敏感性分析产生相似的结果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: No head-to-head trials compared the efficacy of transarterial radioembolization (TARE, also known as selective internal radiation therapy) to combination immunotherapy in hepatocellular carcinoma (HCC). The analysis objective was to compare effectiveness outcomes of TARE using Y-90 resin microspheres and atezolizumab-bevacizumab (AB) in advanced unresectable HCC. METHODS: Patient-level data from SARAH randomized controlled trial for TARE and aggregate real-world data from AB-real study were used in an unanchored matching-adjusted indirect comparison. The basecase analysis used per-protocol data from SARAH; intention-to-treat data were used in sensitivity analyses. The following prognostic variables and effect modifiers were identified from literature: cause of disease, macrovascular invasion, Eastern Cooperative Oncology Group Performance Status, alpha-fetoprotein level and albumin-bilirubin score. Weights were assigned to patients from SARAH to balance baseline characteristics across studies and reflect characteristics of AB-real patients. Overall survival (OS), progression-free survival (PFS) and response rates (overall response rates [ORR]) were calculated and compared. RESULTS: The analysis of OS and PFS included 140 patients receiving TARE and 131 for the analysis of response rates, compared to 202 receiving AB. Median OS was 15.0 and 14.9 months for TARE and AB, respectively (HR=0.980; 95% confidence interval [CI]: 0.658-1.461; p-value=0.922). Median PFS was 4.4 and 6.8 months for TARE and AB, respectively (HR=0.745; 95%CI: 0.544-1.022; p-value=0.068). ORR were 19.8% and 25% with TARE and AB, respectively (OR for AB=1.386, 95%CI: 0.746-2.668; p-value=0.306). Sensitivity analyses generated similar results. CONCLUSION: In HCC patients receiving treatment, TARE using Y-90 resin microspheres may achieve comparable effectiveness outcomes compared with AB.
引用
- Agirrezabal I, Bouattour M, Pinato DJ, et al. Efficacy of transarterial radioembolization using Y-90 resin microspheres versus atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A matching-adjusted indirect comparison. Eur J Cancer. 2023. PMID: 37988840. doi:10.1016/j.ejca.2023.113427
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。